计算溶液所需的质量、体积或浓度。
活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
---|
货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
---|---|---|---|---|
G413546-5mg |
5mg |
现货 ![]() |
| |
G413546-10mg |
10mg |
现货 ![]() |
| |
G413546-25mg |
25mg |
现货 ![]() |
| |
G413546-50mg |
50mg |
现货 ![]() |
| |
G413546-100mg |
100mg |
现货 ![]() |
|
别名 | N-(4-乙基苯基)-3-(羟甲基)-N-异丁基-4-((四氢-2H-吡喃-4-基)甲氧基)苯磺酰胺 |
---|---|
英文别名 | GSK-2981278;GSK 2981278;ROR gama modulator 1 | 1474110-21-8 | s6610 | BS-15442 | N-(4-ethylphenyl)-3-(hydroxymethyl)-N-isobutyl-4-((tetrahydro-2H-pyran-4-yl)methoxy)benzenesulfonamide | UNII-L49V5G013I | HY-19770 | ZIC11021 | N-(4-ethylphenyl)-3-(hydroxym |
规格或纯度 | Moligand™, ≥98% |
英文名称 | GSK2981278 |
生化机理 | GSK2981278 是一种高效力、高选择性的 RORγ 反激动剂。 |
储存温度 | -20°C储存 |
运输条件 | 超低温冰袋运输 |
作用类型 | 激动剂 |
作用机制 | RAR 相关孤儿受体-γ 的激动剂 |
产品介绍 |
说明: GSK2981278是强效的RORγ反向激动剂。 Information GSK2981278 GSK2981278 is a highly potent and selective inverse agonist for RORγ . Targets RORγ In vitro GSK2981278 has no significant effect on RORα-dependent activation. GSK2981278 significantly inhibits production of the Th17 signature (IL-17A, IL-17F, IL-22 and IL-23) in multiple in vitro and human tissue-based assays. In vivo GSK2981278 attenuates inflammation in a mouse model of psoriasis. Topical treatment with GSK2981278 will significantly limit Th17-type cytokine expression and should therefore lead to improved clinical outcomes for patients. |
ALogP | 4.456 |
---|---|
HBD Count | 1 |
Rotatable Bond | 10 |
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
---|
PubChem SID | 504772553 |
---|---|
分子类型 | 小分子 |
IUPAC Name | N-(4-ethylphenyl)-3-(hydroxymethyl)-N-(2-methylpropyl)-4-(oxan-4-ylmethoxy)benzenesulfonamide |
INCHI | InChI=1S/C25H35NO5S/c1-4-20-5-7-23(8-6-20)26(16-19(2)3)32(28,29)24-9-10-25(22(15-24)17-27)31-18-21-11-13-30-14-12-21/h5-10,15,19,21,27H,4,11-14,16-18H2,1-3H3 |
InChi Key | LZLBRISQTJVZNP-UHFFFAOYSA-N |
Canonical SMILES | CCC1=CC=C(C=C1)N(CC(C)C)S(=O)(=O)C2=CC(=C(C=C2)OCC3CCOCC3)CO |
Isomeric SMILES | CCC1=CC=C(C=C1)N(CC(C)C)S(=O)(=O)C2=CC(=C(C=C2)OCC3CCOCC3)CO |
PubChem CID | 89875987 |
分子量 | 461.61 |
溶解性 | Solubility (25°C) In vitro DMSO: 92 mg/mL (199.3 mM); Ethanol: 92 mg/mL (199.3 mM); Water: Insoluble; |
---|---|
DMSO(mg / mL) Max Solubility | 92 |
DMSO(mM) Max Solubility | 199.302441454908 |
Water(mg / mL) Max Solubility | <1 |
分子量 | 461.600 g/mol |
XLogP3 | 4.400 |
氢键供体数Hydrogen Bond Donor Count | 1 |
氢键受体数Hydrogen Bond Acceptor Count | 6 |
可旋转键计数Rotatable Bond Count | 10 |
精确质量Exact Mass | 461.224 Da |
单同位素质量Monoisotopic Mass | 461.224 Da |
拓扑极表面积Topological Polar Surface Area | 84.500 Ų |
重原子数Heavy Atom Count | 32 |
形式电荷Formal Charge | 0 |
复杂度Complexity | 635.000 |
同位素原子数Isotope Atom Count | 0 |
定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
所有立体化学键的总数The total count of all stereochemical bonds | 0 |
共价键合单元计数Covalently-Bonded Unit Count | 1 |
NMR Spectrum 1H | Conforms to Structure |
---|---|
Purity(HPLC) | 98-100(%) |
1. Skepner J, Ramesh R, Trocha M, Schmidt D, Baloglu E, Lobera M, Carlson T, Hill J, Orband-Miller LA, Barnes A et al.. (2014) Pharmacologic inhibition of RORγt regulates Th17 signature gene expression and suppresses cutaneous inflammation in vivo.. J Immunol, 192 (6): (2564-75). [PMID:24516202] [10.1021/op500134e] |
2. Smith SH, Peredo CE, Takeda Y, Bui T, Neil J, Rickard D, Millerman E, Therrien JP, Nicodeme E, Brusq JM et al.. (2016) Development of a Topical Treatment for Psoriasis Targeting RORγ: From Bench to Skin.. PLoS ONE, 11 (2): (e0147979). [PMID:26870941] [10.1021/op500134e] |